Screen Shot 2017-03-06 at 5.15.58 PM.png
 
 

Miromatrix is on a mission to eliminate the organ transplant waiting list.

Core Technology

Perfusion Decellularization

Organ regeneration begins with pristine decellularized extracellular matrix organ scaffolds.  We own the patented perfusion decellularization technology used in our whole organ regeneration programs and FDA cleared products.

Perfusion Recellularization

Our decellularized organs are the ideal template to support the growth and differentiation of cells into functional organs. Today we are using our proprietary perfusion recellularization process to engineer transplantable organs. 


Organ ProgramS

Our goal is to eliminate the organ transplant waiting list.

End-stage liver disease (ESLD) is the 8th leading cause of death in the United States, accounting for 40,000 deaths annually.  The only curative therapy for ESLD is liver transplantation. Unfortunately, the success of liver transplantation has led to its greatest challenge, the shortage of available organs.  Nationally, about 16,000 patients per year are waiting for liver transplantation.  Two-thirds won’t receive a liver.  We can change that.

 


Over 400,000 individuals have end-stage kidney disease requiring hemodialysis in the United States, with approximately 100,000 individuals awaiting a kidney transplant.  Due to the chronic shortage of transplantable kidneys, less than 20,000 kidneys are transplanted annually.  The five-year survival rate for those on dialysis is ~35%.  The need for a new source of transplantable kidneys is greater than ever.  

 

Newsroom